Our new Global Head of Drug Development and Chief Medical Officer

Ellipses Pharma Announces Appointment of Professor Hendrik-Tobias Arkenau as Global Head of Drug Development and Chief Medical Officer

Highly Accomplished Oncologist with Proven Track Record in Leading Innovative Drug Development

Ellipses Pharma a global drug development company focused on accelerating the development of new oncology treatments, announces the appointment of Professor Arkenau as Global Head of Drug Development and Chief Medical Officer. In this role, Professor Arkenau will lead Ellipses’ drug development efforts, incorporating clinical strategy, scientific affairs and clinical development to drive innovation and efficiency as Ellipses Pharma continues to grow and develop its portfolio of oncology assets.

Professor Arkenau is a world-class expert and global authority in the clinical and translational development of cancer treatments. His experience, built across a career spanning over 300 oncology trials at all stages of development, will strengthen the team’s already extensive knowledge and experience in oncology drug development. His appointment further validates Ellipses’ approach to de-risking and accelerating the development of treatments for patients.

Prior to joining Ellipses, Professor Arkenau was the Executive Medical Director of Sarah Cannon Research Institute UK, where for the last 12 years he led a broad portfolio of early and translational oncology assets and successfully supported multiple pharma and biotech companies in their strategic development. Sarah Cannon is part of HCA Healthcare, the largest private healthcare provider in the world. Professor Arkenau was also responsible for the integration of innovative new cancer and molecular diagnostics into the HCA Healthcare group.

Professor Arkenau is an Honorary Professor at University College London and an Honorary Consultant Oncologist at University College London Hospital. Previously, he was Senior Clinical Fellow at the Royal Marsden hospital, and team leader for early drug development at the Prince of Wales Clinical School, University of New South Wales, Australia.

Rajan Jethwa, CEO and Founder of Ellipses Pharma, commented: “I am delighted that Tobi has chosen to join us at such an exciting and pivotal time in our evolution. Tobi brings a wealth of oncology experience across the drug development landscape and continues to be driven by the goal of improving the treatment opportunities for cancer patients. He has had an exceptional career in drug development, and his clinical expertise, patient-centric mindset, and organisational leadership experience make him ideally qualified to join the senior leadership as we embark on our next chapter.”

Professor Arkenau said: “I am honoured to join Ellipses and look forward to working closely with Ellipses’ talented team as we continue to grow the business by driving transformational new cancer drugs through the clinic. Leading on Ellipses’ accelerated approach to drug development in oncology is a unique opportunity to develop highly promising treatments that have the potential to deliver a meaningful impact on patients’ lives. I look forward to being able to leverage my extensive experience in oncology, drug development strategy and patient care to support Ellipses as it strives for clinical and commercial success.”

Professor Sir Chris Evans, Chairman of Ellipses, said “After a thorough and rigorous global selection process we are thrilled to have Tobi join Ellipses. We look forward to benefiting from his strategic insights and clinical leadership as we continue evolving and executing our plans”